相关实验视频

Updated: Jul 5, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

铁死诱导剂在复发的三阴性乳腺癌中抑制PD-L1

Christophe Desterke¹, Yao Xiang², Rima Elhage^2,3

¹UFR Médecine-INSERM UMRS1310, Université Paris-Saclay, F-94800 Villejuif, France.

|January 11, 2024

概括

铁灭诱导剂在三阴性乳腺癌 (TNBC) 中增加PD-L1 (CD274),增强免疫治疗的有效性. 一个CD274铁死驱动因子得分预测了乳腺癌患者的预后和复发风险.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物化学生物化学

背景情况:

三重阴性乳腺癌 (TNBC) 的复发率很高,新辅助化疗和抗PD-L1免疫疗法显示出治疗效益.
了解铁和免疫调节之间的相互作用对于改善TNBC治疗策略至关重要.

研究的目的:

研究铁灭菌诱导剂对TNBC中免疫相关基因表达的影响.
开发和验证铁亡驱动因子评分,用于预测乳腺癌的预后和复发风险.

主要方法:

用铁灭诱导剂 (Erastin,RSL3) 治疗的TNBC细胞的整合性奥米克分析以及单细胞/质谱数据.
使用TCGA和METABRIC乳腺瘤队列进行的临床关联分析.
在乳腺癌干细胞和瘤中对关键基因表达的蛋白质水平验证.

主要成果:

铁灭诱导剂在TNBC细胞中调节了CD274 (PD-L1),与整体存活率相关.
瘤中的高CD274表达与上调的铁亡驱动因素 (IDO1,IFNG,TNFAIP3) 和更差的预后有关.
CD274铁灭菌驱动因子得分根据复发风险对患者进行了分层分类,并且与临床因素独立的整体存活率相关.

结论:

铁灭诱导剂在TNBC中增强PD-L1表达,这表明对高危患者的抗PD-L1免疫疗法具有协同作用的潜力.
CD274铁死驱动因子得分作为乳腺癌复发的预后生物标志物.
与免疫疗法一起向铁衰可能为复发性TNBC提供一种新的策略.

关键词:

CD274 是一个CD274 美国TNBC电视台这是一个基本的基础.乳腺癌乳腺癌乳腺癌铁性化 (ferroptosis) 是一种免疫疗法免疫疗法

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

Necrosis

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...